Gilead: Bictegravir/Lenacapavir Combo Shows Non-Inferiority in HIV Switch Trial
Event summary
- Gilead’s Phase 3 ARTISTRY-2 trial demonstrated its investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was non-inferior to BIKTARVY in virologically suppressed HIV patients.
- The trial, completed in December 2025, evaluated a 2:1 switch from BIKTARVY to BIC/LEN, with the primary endpoint assessed at Week 48.
- Topline results from ARTISTRY-1, announced in November 2025, also showed BIC/LEN to be well-tolerated and non-inferior to multi-tablet regimens.
- BIC/LEN combines bictegravir (an integrase strand transfer inhibitor) with lenacapavir (a first-in-class capsid inhibitor).
The big picture
Gilead’s ARTISTRY trials represent a continued effort to refine HIV treatment regimens, focusing on simplified dosing and novel mechanisms of action. The non-inferiority result for BIC/LEN, while not a blockbuster outcome, expands Gilead’s portfolio and provides an alternative for patients already on BIKTARVY. This development underscores the ongoing evolution of HIV therapeutics, moving towards more patient-friendly and potentially curative approaches, though Gilead's dominance in the space faces increasing competition.
What we're watching
- Regulatory Approval
- The combined ARTISTRY-1 and ARTISTRY-2 data will be submitted for regulatory approval, and the speed of this process will dictate the timeline for potential market entry and revenue generation.
- Market Adoption
- The success of BIC/LEN will depend on physician and patient adoption, which will be influenced by factors such as pricing, reimbursement, and perceived benefits over existing therapies.
- Long-Acting Potential
- Gilead’s ongoing development of lenacapavir as a long-acting option could significantly alter the HIV treatment landscape, potentially cannibalizing demand for BIC/LEN and requiring a strategic shift in product positioning.
Related topics